AA
RIGL icon

Ancora Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Ancora Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,500
Closed -$58K – 491
2014
Q1 		$58K Buy
+1,500
New +$53.5K 0.01% 441

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Ancora Advisors's RIGL Position: Q2 2014 in Review

Ancora Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2014, closing a stake of 1,500 shares — an estimated $58K sold.

Ancora Advisors first reported a position in RIGL in Q1 2014 and held it in 1 quarter. The position peaked at $58K in Q1 2014. 103 funds tracked by Wall St. Rank hold RIGL as of Q2 2014.

  • Ancora Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Ancora Advisors sold 1,500 Rigel Pharmaceuticals shares in Q2 2014, an estimated $58K.
  • Ancora Advisors first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • Ancora Advisors's Rigel Pharmaceuticals position peaked at $58K in Q1 2014.
  • 103 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2014.

Based on Ancora Advisors's 13F filing for Q2 2014, filed 31 Jul 2014.